In this video interview, Douglas K. Devries, OD, discusses the negative impact of undiagnosed and untreated ocular surface disease. He give pearls for comanaging cataract surgery patients, screening for meibomian gland dysfunction, and approaching OSD management in patients with comorbid conditions.
Supported by unrestricted educational grants from Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision
Identify methods to improve surgical, and ocular surface and corneal disease outcomes through comanagement of cataract, refractive, and corneal patients
Describe the impact that OSD has on contact lens wear and drop out as well as overall cataract and refractive surgery outcomes
Compare and contrast traditional and new and emerging diagnostic tests in classifying ocular surface disease severity and differentiating MGD
Increase confidence in making therapeutic decisions for OSD patients based on disease classification, including acute exacerbations of dry eye disease, chronic dry eye, and MGD
Explore approaches to ocular surface toxicity when OSD patients are treated for comorbid conditions
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Douglas K. Devries, OD, Moderator
Co-Founder and Managing Partner
Eye Care Associates of Nevada
Sparks, Nevada
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Douglas K. Devries, OD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Speakers Bureau: Alcon, Bausch+ Health, Bio Tissue, Dompe, Eyevance, Johnson & Johnson Vision, Lumeris, Novartis, OcuSoft, Sun, and TearLab, Share/Stockholder: RPS.
EDITORIAL DISCLOSURES
Erin K. Fletcher, MIT, director of compliance and education; Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Carl Zeiss Meditec, Glaukos, or Johnson & Johnson Vision.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
1.00 program creditDouglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
